The US Food and Drug Administration recently extended the comment period on a controversial draft guidance document that would recommend stronger patient safety guidelines for Laser-Assisted In-Situ Keratomileusis (LASIK) surgery, but plenty of stakeholders from all sides of the issue have already had their say.
LASIK Comments Show Divided Opinions As FDA Extends Feedback Period
The comment period for a draft guidance document on labeling for LASIK surgery equipment has been extended for another month. Ninety people have already filed comments, representing a wide range of views about the procedure.
More from Guidance
• By
Medtech Insight sat down with Arcadia's chief strategy officer Aneesh Chopra to discuss interoperability, industry standards and the future of health care data and AI.
• By
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 30 documents have been posted on the tracker since its last update.
• By
Two US FDA device center websites have been restored under a restraining order. The pages now carry a disclaimer alleging they include "extremely inaccurate" content about gender; however, neither site includes any substantive discussion of trans issues.
• By
Medtechs watch with interest as NICE, a long-standing component of market access for innovative technologies in the National Health Service, vows to get to grips with technology programs that often miss the target for developers of groundbreaking solutions.
More from Compliance
• By
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
• By
Data recently published in The BMJ found that almost 30% of device adverse event reports filed with the US FDA are late or missing accurate date information. A relatively small number of companies account for more than half of the late reports.
• By
Medtech Insight sat down with Arcadia's chief strategy officer Aneesh Chopra to discuss interoperability, industry standards and the future of health care data and AI.